-$0.14 EPS Expected for Calithera Biosciences, Inc. (NASDAQ:CALA) This Quarter

Equities analysts predict that Calithera Biosciences, Inc. (NASDAQ:CALAGet Rating) will announce earnings of ($0.14) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Calithera Biosciences’ earnings. The lowest EPS estimate is ($0.14) and the highest is ($0.13). Calithera Biosciences reported earnings per share of ($0.19) in the same quarter last year, which suggests a positive year-over-year growth rate of 26.3%. The company is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Calithera Biosciences will report full-year earnings of ($0.59) per share for the current fiscal year, with EPS estimates ranging from ($0.68) to ($0.51). For the next year, analysts expect that the company will report earnings of ($0.36) per share, with EPS estimates ranging from ($0.52) to ($0.25). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Calithera Biosciences.

Calithera Biosciences (NASDAQ:CALAGet Rating) last announced its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.18). During the same quarter in the prior year, the company posted ($0.28) earnings per share.

A number of research analysts have recently commented on the stock. Zacks Investment Research cut shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 12th. LADENBURG THALM/SH SH decreased their price target on shares of Calithera Biosciences from $3.00 to $1.50 in a research note on Wednesday, May 11th. StockNews.com started coverage on shares of Calithera Biosciences in a report on Friday. They set a “hold” rating on the stock. Finally, SVB Leerink lowered their price target on shares of Calithera Biosciences from $3.00 to $2.00 and set an “outperform” rating for the company in a research report on Monday, April 4th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $2.00.

Several institutional investors and hedge funds have recently bought and sold shares of CALA. Morgan Stanley raised its holdings in shares of Calithera Biosciences by 288,904.1% in the second quarter. Morgan Stanley now owns 985,504 shares of the biotechnology company’s stock worth $2,060,000 after buying an additional 985,163 shares during the last quarter. Bank of America Corp DE raised its stake in Calithera Biosciences by 90.4% in the 2nd quarter. Bank of America Corp DE now owns 100,212 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 47,568 shares during the last quarter. Raymond James Financial Services Advisors Inc. acquired a new stake in Calithera Biosciences during the 3rd quarter worth about $27,000. Geode Capital Management LLC lifted its position in Calithera Biosciences by 16.3% during the 3rd quarter. Geode Capital Management LLC now owns 804,384 shares of the biotechnology company’s stock worth $1,753,000 after acquiring an additional 112,622 shares during the period. Finally, Primecap Management Co. CA grew its stake in Calithera Biosciences by 2.6% during the 3rd quarter. Primecap Management Co. CA now owns 10,608,700 shares of the biotechnology company’s stock valued at $23,127,000 after purchasing an additional 265,000 shares during the last quarter. Hedge funds and other institutional investors own 55.84% of the company’s stock.

CALA traded down $0.01 during trading hours on Monday, reaching $0.22. 45,773 shares of the company’s stock traded hands, compared to its average volume of 2,742,022. The firm has a 50-day moving average price of $0.34 and a 200 day moving average price of $0.53. Calithera Biosciences has a 52-week low of $0.15 and a 52-week high of $2.59. The firm has a market capitalization of $17.44 million, a PE ratio of -0.15 and a beta of 1.64.

About Calithera Biosciences (Get Rating)

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology.

See Also

Get a free copy of the Zacks research report on Calithera Biosciences (CALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.